Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

R Karabudak

Showing results (11-20 of 19) with videos related to

Pageof 2
Sort By:
You have reached the last page of results.This site can display upto 19 results.
Journal of Neuroimmunology|May 20, 1998
Alpha interferon treatment in myasthenia gravis: effects on natural killer cell activityH Bolay, R Karabudak, C Aybay, et al.
Acta Neurologica Scandinavica|May 12, 2010
Analysis of BAFF and TRAIL expression levels in multiple sclerosis patients: evaluation of expression under immunomodulatory therapyA Kurne, D Guc, H Canpinar, et al.
Neurology|September 25, 1998
Survival and predictors of disability in Turkish MS patients. Turkish Multiple Sclerosis Study Group (TUMSSG)O Kantarci, A Siva, M Eraksoy, et al.
European Journal of Neurology|January 20, 2006
A recommended treatment algorithm in relapsing multiple sclerosis: report of an international consensus meetingD Karussis, L D Biermann, S Bohlega, et al.
Multiple Sclerosis and Related Disorders|October 11, 2020
Shorter infusion time of ocrelizumab: Results from the randomized, double-blind ENSEMBLE PLUS substudy in patients with relapsing-remitting multiple sclerosisH-P Hartung, T Berger, R A Bermel, et al.
Multiple Sclerosis (Houndmills, Basingstoke, England)|December 11, 2013
Characterization of neuromyelitis optica and neuromyelitis optica spectrum disorder patients with a late onsetN Collongues, R Marignier, A Jacob, et al.
Multiple Sclerosis and Related Disorders|May 3, 2021
The outcome of a national MS-Covid-19 study: What the Turkish MS cohort reveals?S Sen, R Karabudak, I Schiavetti, et al.
Journal of Medical Economics|December 12, 2023
Comparative effectiveness and cost-effectiveness of natalizumab and fingolimod in rapidly evolving severe relapsing-remitting multiple sclerosis in the United KingdomT Spelman, W L Herring, C Acosta, et al.
BMC Medical Research Methodology|May 31, 2022
Impact of methodological choices in comparative effectiveness studies: application in natalizumab versus fingolimod comparison among patients with multiple sclerosisM Lefort, S Sharmin, J B Andersen, et al.
Pageof 2

Showing results (11-20 of 19) with videos related to

Sort By:
Pageof 2
You have reached the last page of results.This site can display upto 19 results.
Journal of Neuroimmunology|May 20, 1998
Alpha interferon treatment in myasthenia gravis: effects on natural killer cell activityH Bolay, R Karabudak, C Aybay, et al.
Acta Neurologica Scandinavica|May 12, 2010
Analysis of BAFF and TRAIL expression levels in multiple sclerosis patients: evaluation of expression under immunomodulatory therapyA Kurne, D Guc, H Canpinar, et al.
Neurology|September 25, 1998
Survival and predictors of disability in Turkish MS patients. Turkish Multiple Sclerosis Study Group (TUMSSG)O Kantarci, A Siva, M Eraksoy, et al.
European Journal of Neurology|January 20, 2006
A recommended treatment algorithm in relapsing multiple sclerosis: report of an international consensus meetingD Karussis, L D Biermann, S Bohlega, et al.
Multiple Sclerosis and Related Disorders|October 11, 2020
Shorter infusion time of ocrelizumab: Results from the randomized, double-blind ENSEMBLE PLUS substudy in patients with relapsing-remitting multiple sclerosisH-P Hartung, T Berger, R A Bermel, et al.
Multiple Sclerosis (Houndmills, Basingstoke, England)|December 11, 2013
Characterization of neuromyelitis optica and neuromyelitis optica spectrum disorder patients with a late onsetN Collongues, R Marignier, A Jacob, et al.
Multiple Sclerosis and Related Disorders|May 3, 2021
The outcome of a national MS-Covid-19 study: What the Turkish MS cohort reveals?S Sen, R Karabudak, I Schiavetti, et al.
Journal of Medical Economics|December 12, 2023
Comparative effectiveness and cost-effectiveness of natalizumab and fingolimod in rapidly evolving severe relapsing-remitting multiple sclerosis in the United KingdomT Spelman, W L Herring, C Acosta, et al.
BMC Medical Research Methodology|May 31, 2022
Impact of methodological choices in comparative effectiveness studies: application in natalizumab versus fingolimod comparison among patients with multiple sclerosisM Lefort, S Sharmin, J B Andersen, et al.
Pageof 2